Trial Profile
Comparing Patient Satisfaction Throughout the Day With PATADAY (OLOPATADINE HYDROCHLORIDE) 0.2% QD or BEPREVE (BEPOTASTINE BESILATE OPHTHALMIC SOLUTION) 1.5% BID
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Feb 2014
Price :
$35
*
At a glance
- Drugs Olopatadine (Primary) ; Bepotastine
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- 07 Feb 2014 New trial record